(UroToday.com) Dr. Henk Luiting discussed the utility of histological confirmation for intraprostatic recurrences on PSMA PET/CT after prostate whole gland radiotherapy at the European Association of Urology (EAU) 2021 annual meeting’s detection of recurrence and salvage treatment options after primary treatment of prostate cancer session. Patients with an intraprostatic recurrence after radiotherapy can be considered for salvage therapy, however, the EAU guidelines recommend obtaining histological confirmation before salvage therapy. This recommendation, however, does not consider the diagnostic accuracy of PSMA PET/CT. In current daily clinical practice, the need to obtain histological confirmation is often deemed unnecessary as a result of the recognized high specificity of PSMA PET/CT, which currently is the modality of choice for detecting recurrences. The objective of this study was to evaluate the biopsy outcomes in patients with an intraprostatic recurrence on PSMA PET/CT after prostate whole gland radiotherapy.